CalciMedica Form 4: 54.8K Options Issued to Director Allan Shaw
Rhea-AI Filing Summary
CalciMedica, Inc. (CALC) – Form 4 insider filing dated 26 June 2025
The filing discloses that director Allan Shaw received four separate option grants covering an aggregate 54,844 shares of common stock on 24 June 2025. Three grants, totaling 44,844 options, carry an exercise price of $1.53 and expire on 22 April 2035. A fourth grant of 10,000 options has an exercise price of $1.65 and expires on 23 June 2035.
The awards were approved by the Board on 23 April 2025, but were contingent upon shareholder approval of an amendment to the company’s 2023 Equity Incentive Plan. That amendment was ratified on 24 June 2025, making the options effective the same day.
Vesting schedules are as follows:
- 10,000 options (Grant #1): 1/12 monthly over one year beginning 26 March 2025.
- 8,594 options (Grant #2): fully exercisable immediately.
- 26,250 options (Grant #3): 1/9 monthly over one year beginning 1 April 2025.
- 10,000 options (Grant #4): 1/12 monthly over one year beginning 24 June 2025; fully vested no later than the 2026 annual meeting.
No purchases or sales of already-outstanding common shares were reported, and all securities remain held directly by the reporting person. The filing is a routine incentive-compensation disclosure and does not indicate any change in the director’s ownership of non-derivative equity.
Positive
- None.
Negative
- None.
Insights
TL;DR – Routine option grants; no cash outlay; neutral signal.
The Form 4 shows standard, board-approved equity incentives rather than open-market activity. Total options (54,844) equate to a modest slice of CALC’s float and carry low exercise prices roughly aligned with recent trading levels, implying minimal immediate dilution risk. Because the grants vest over one year (some immediately), they strengthen alignment without affecting near-term cash flow or signaling insider sentiment via purchase/sale. For valuation, these options are already contemplated under GAAP share-based-compensation expense and thus have negligible incremental impact. Overall market effect: neutral.
TL;DR – Board- and shareholder-approved equity plan; governance compliant.
The options were contingent upon shareholder approval of the amended 2023 Equity Incentive Plan, demonstrating adherence to good governance practices. Vesting schedules promote ongoing engagement, and a 10b5-1 plan checkbox is present, offering potential affirmative-defense coverage. No red flags regarding excessive compensation or undisclosed arrangements appear. Hence, from a governance standpoint, the filing is routine and poses no material concern.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Director Stock Option (Right to Buy) | 10,000 | $0.00 | -- |
| Grant/Award | Director Stock Option (Right to Buy) | 8,594 | $0.00 | -- |
| Grant/Award | Director Stock Option (Right to Buy) | 26,250 | $0.00 | -- |
| Grant/Award | Director Stock Option (Right to Buy) | 10,000 | $0.00 | -- |
Footnotes (1)
- The option grant was approved by the Board of Directors of CalciMedica, Inc. (the "Company") on April 23, 2025, subject to stockholder approval of an amendment of the Company's 2023 Equity Incentive Plan (the "Amended 2023 EIP") under which the option was granted. The Company's stockholders approved the Amended 2023 EIP on June 24, 2025. 1/12th of the shares subject to the option vest in equal monthly installments over a one year period following March 26, 2025. Immediately exercisable. 1/9th of the shares subject to the option vest in equal monthly installments over a one year period following April 1, 2025. 1/12th of the shares subject to the option vest in equal monthly installments over a one year period following June 24, 2025, provided that the shares will in any case be fully vested on the date of Company's 2026 annual meeting of stockholders.
